BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36512304)

  • 1. ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer.
    Wang R; Gao D; Chen C; Fan G; Cheng H; Tao Y; Lu J; Tian J; Wang Y; Wang Z
    Clin Transl Oncol; 2023 May; 25(5):1425-1435. PubMed ID: 36512304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.
    Xu J; Wang Y; Jiang J; Yin C; Shi B
    J Transl Med; 2023 Jan; 21(1):56. PubMed ID: 36717944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.
    Wang J; Zhang Z; Li R; Mao F; Sun W; Chen J; Zhang H; Bartsch JW; Shu K; Lei T
    Biomed Pharmacother; 2018 Jan; 97():1066-1077. PubMed ID: 29136943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells.
    Wang X; Wang Y; Gu J; Zhou D; He Z; Wang X; Ferrone S
    Sci Rep; 2017 Aug; 7(1):9687. PubMed ID: 28852196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
    Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
    Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.
    Ruff M; Leyme A; Le Cann F; Bonnier D; Le Seyec J; Chesnel F; Fattet L; Rimokh R; Baffet G; Théret N
    PLoS One; 2015; 10(9):e0139179. PubMed ID: 26407179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
    Adam L; Zhong M; Choi W; Qi W; Nicoloso M; Arora A; Calin G; Wang H; Siefker-Radtke A; McConkey D; Bar-Eli M; Dinney C
    Clin Cancer Res; 2009 Aug; 15(16):5060-72. PubMed ID: 19671845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways.
    Li K; Quan L; Huang F; Li Y; Shen Z
    Int Immunopharmacol; 2023 Sep; 122():110580. PubMed ID: 37418984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner.
    Amantini C; Morelli MB; Nabissi M; Cardinali C; Santoni M; Gismondi A; Santoni G
    Oncotarget; 2016 Aug; 7(31):50180-50194. PubMed ID: 27367032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
    Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
    Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
    Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
    Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
    Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
    Li B; Xie D; Zhang H
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
    Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
    Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
    Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
    Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMGN5 promotes IL-6-induced epithelial-mesenchymal transition of bladder cancer by interacting with Hsp27.
    Yao K; He L; Gan Y; Liu J; Tang J; Long Z; Tan J
    Aging (Albany NY); 2020 Apr; 12(8):7282-7298. PubMed ID: 32315283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.
    Roy R; Dagher A; Butterfield C; Moses MA
    Mol Cancer Res; 2017 Nov; 15(11):1608-1622. PubMed ID: 28765266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.
    Islam SS; Mokhtari RB; Noman AS; Uddin M; Rahman MZ; Azadi MA; Zlotta A; van der Kwast T; Yeger H; Farhat WA
    Mol Carcinog; 2016 May; 55(5):537-51. PubMed ID: 25728352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.